Company announces positive topline results from PROTECTIVE-2 phase 3 trial of plinabulin in combination with pegfilgrastim for prevention of chemotherapy-induced neutropenia

Study (n=221) primary endpoint showing statistically significant improvement (p=0.0015) in rate of prevention of grade 4 neutropenia in cycle 1 with plinabulin and pegfilgrastim combination therapy vs. single dose of pegfilgrastim as monotherapy (31.5 vs. 13.6%, respectively).

SPS commentary:

Plinabulin is an investigational differentiated immune and stem cell modulator, currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate chemotherapy-induced neutropenia (CIN). FDA has granted it Breakthrough Therapy designation for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN).

Biospace Inc.